10:54 AM EDT, 03/26/2024 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Tuesday that the UK's Medicines and Healthcare Products Regulatory Agency has cleared its clinical trial authorization application for BEAM-302, which is intended for the treatment of alpha-1 antitrypsin deficiency, an inherited genetic disorder.

The company said it intends to roll out a phase 1/2 trial of BEAM-302 in the UK in H1. The trial will be an open-label, dose-escalation study that is intended to evaluate the drug candidate's safety, pharmacodynamics, pharmacokinetics and efficacy.

Shares of Beam Therapeutics ( BEAM ) were down 0.2% in recent trading on Tuesday.

Price: 33.63, Change: -0.06, Percent Change: -0.19